68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer

Conditions

large cell neuroendocrine lung cancer, small cell lung cancer

Brief summary

The fraction of patients with SCLC and LCNEC who have at least one malignant lesion that can be identified with 68Ga-satoreotide trizoxetan-PET

Detailed description

Number and location of lesions that have been identified by 68Ga-satoreotide trizoxetan-PET in each patient will be compared with the number and location of known malignant lesions (identified by previous CT-scans, and if available, [18F]FDG-PET/CT) to evaluate the lesion-based diagnostic efficacy and to describe sites of disagreement., SUVmax, SUVpeak, SUVmean, and functional tumor volume delineated by 68Ga-satoreotide trizoxetan-PET will be measured in the identified malignant lesions, SUVmax and SUVpeak will be measured in background organs (e.g., lung, kidney, spleen, liver, lymph nodes, and brain)., The quantitative parameters in the malignant lesions will be divided by the corresponding 68Ga-satoreotide trizoxetan-uptake in background organs to estimate tumor-to-background ratio.

Related papers

No related papers found yet.

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The fraction of patients with SCLC and LCNEC who have at least one malignant lesion that can be identified with 68Ga-satoreotide trizoxetan-PET	—

Secondary

Measure	Time frame
Number and location of lesions that have been identified by 68Ga-satoreotide trizoxetan-PET in each patient will be compared with the number and location of known malignant lesions (identified by previous CT-scans, and if available, [18F]FDG-PET/CT) to evaluate the lesion-based diagnostic efficacy and to describe sites of disagreement., SUVmax, SUVpeak, SUVmean, and functional tumor volume delineated by 68Ga-satoreotide trizoxetan-PET will be measured in the identified malignant lesions, SUVmax and SUVpeak will be measured in background organs (e.g., lung, kidney, spleen, liver, lymph nodes, and brain)., The quantitative parameters in the malignant lesions will be divided by the corresponding 68Ga-satoreotide trizoxetan-uptake in background organs to estimate tumor-to-background ratio.	—

Measure

Time frame

Number and location of lesions that have been identified by 68Ga-satoreotide trizoxetan-PET in each patient will be compared with the number and location of known malignant lesions (identified by previous CT-scans, and if available, [18F]FDG-PET/CT) to evaluate the lesion-based diagnostic efficacy and to describe sites of disagreement., SUVmax, SUVpeak, SUVmean, and functional tumor volume delineated by 68Ga-satoreotide trizoxetan-PET will be measured in the identified malignant lesions, SUVmax and SUVpeak will be measured in background organs (e.g., lung, kidney, spleen, liver, lymph nodes, and brain)., The quantitative parameters in the malignant lesions will be divided by the corresponding 68Ga-satoreotide trizoxetan-uptake in background organs to estimate tumor-to-background ratio.

—

Countries

Denmark

Outcome results